FindTrial
Sign In

A PHASE II, MULTI-CENTER STUDY OF MELPHALAN 100 mg/m2 (MEL 100) as transplant, REVLIMID and PREDNISONE (RP) as consolidation and REVLIMID ALONE as maintenance IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.

A PHASE II, MULTI-CENTER STUDY OF MELPHALAN 100 mg/m2 (MEL 100) as transplant, REVLIMID and PREDNISONE (RP) as consolidation and REVLIMID ALONE as maintenance IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-004730-41-IT
Enrollment
95
Registered
2007-11-07
Start date
2005-11-16
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TREATMENT FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. MedDRA version: 6.1 Level: PT Classification code 10028228

Interventions

Trade Name: DELTACORTENE FORTE*10CPR 25MG Pharmaceutical Form: Tablet INN or Proposed INN: Prednisone CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration nu

Sponsors

FONDAZIONE NEOPLASIE SANGUE ONLUS
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026